References

COVID-19 infection: an overview on cytokine storm and related interventions

10.1186/s12985-022-01814-1 · 2022 · External reference

Factors associated with small airway obstruction in COVID-19 survivors: A cross-sectional study among health-care providers

10.52225/narra.v3i3.437 · 2023 · External reference

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies

10.3390/v15010167 · 2023 · External reference

COVID-19: Challenges of Viral Variants

10.1146/annurev-med-042921-020956 · 2023 · External reference

Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression

10.1038/s41598-023-33314-9 · 2023 · External reference

Treatment acceptance and its associated determinants in cancer patients: A systematic review

10.52225/narra.v3i3.197 · 2023 · External reference

Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment

10.1016/s1470-2045(03)01218-x · 2003 · External reference

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

10.1016/s1470-2045(20)30310-7 · 2020 · External reference

Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis

10.1016/j.dsx.2020.07.037 · 2020 · External reference

Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes

10.1038/s41598-021-83108-0 · 2021 · External reference

Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan

10.1001/jamaoncol.2021.2159 · 2021 · External reference

COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis

2023 · External reference

Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021

10.1016/j.vaccine.2023.03.006 · 2023 · External reference

Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

10.1001/jamaoncol.2021.2155 · 2021 · External reference

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment

10.1016/j.ejca.2021.12.006 · 2022 · External reference

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital

10.1080/21645515.2022.2104058 · 2022 · External reference

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

10.1038/s43018-021-00274-w · 2021 · External reference

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

10.1016/j.ccell.2021.12.002 · 2022 · External reference

Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine

10.1001/jamanetworkopen.2022.10780 · 2022 · External reference

Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients

2020 · External reference

Impact of histological subtype on prognosis in stage IV colorectal cancer: A population-based cohort study

10.1371/journal.pone.0264652 · 2022 · External reference

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

10.1016/j.jtho.2015.09.009 · 2016 · External reference

Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation

10.1001/jamaoncol.2022.5974 · 2023 · External reference

Homologous and Heterologous Covid-19 Booster Vaccinations

10.1056/nejmoa2116414 · 2022 · External reference

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

10.1038/s41467-023-38435-3 · 2023 · External reference

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice

2021 · External reference

Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination

2022 · External reference

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

10.1038/s41587-020-0631-z · 2020 · External reference

Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern

10.3390/ijms241914965 · 2023 · External reference

Seroconversion rates following COVID-19 vaccination among patients with cancer

10.1016/j.ccell.2021.06.002 · 2021 · External reference

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status

2021 · External reference

Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant

10.1200/jco.21.02986 · 2022 · External reference

Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines

10.1002/jmv.28032 · 2022 · External reference

SARS-CoV-2 variants and vulnerability at the global level

10.1002/jmv.27717 · 2022 · External reference

Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States

10.1371/journal.pone.0301830 · 2024 · External reference

Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors

10.1002/1878-0261.13359 · 2023 · External reference

Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment

10.1016/j.esmoop.2021.100283 · 2021 · External reference

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

10.1016/j.xcrm.2022.100679 · 2022 · External reference

Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study

10.1001/jamaoncol.2021.5771 · 2022 · External reference

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study

10.3389/fonc.2022.951026 · 2022 · External reference

SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy

10.1093/oncolo/oyac230 · 2023 · External reference

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

10.1016/s0140-6736(20)31173-9 · 2020 · External reference

COVID-19 in cancer patients: The impact of vaccination on outcomes early in the pandemic

10.1002/cam4.6781 · 2023 · External reference

A comparative study of the COVID-19 vaccine efficacy among cancer patients: mRNA versus non-mRNA

10.1371/journal.pone.0281907 · 2023 · External reference

10.1371/journal.pone.0302579 · 2024 · Admitted local publication

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine

2022 · External reference

Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study

2023 · External reference

COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73608 Patients With Cancer and 621475 Matched Controls in Singapore: A Nationwide Cohort Study

10.1001/jamaoncol.2023.2271 · 2023 · External reference

Unresolved reference

External reference

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

10.1186/s12929-022-00853-8 · 2022 · External reference

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

10.1126/science.abn2688 · 2022 · External reference

Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination

10.1038/s41586-021-04120-y · 2021 · External reference

Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy

10.4239/wjd.v13.i9.738 · 2022 · External reference

Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review

10.4239/wjd.v14.i6.892 · 2023 · External reference